fosbretabulin

ZYBRESTAT (fosbretabulin) is currently being evaluated in a pivotal registration study as a potential treatment for anaplastic thyroid cancer (ATC) under a Special Protocol Assessment agreement with the U.S.

unknown title 2009

A Phase II study in platinum-resistant ovarian cancer has been completed and a non-small cell lung cancer study combining fosbretabulin with bevacizumab and platinum based chemotherapy is also ongoing.

unknown title 2009

Like its structural analog, ZYBRESTAT (TM) (fosbretabulin / CA4P), OXi4503 has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis.

News 2009

(Nasdaq: OXGN) (XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the publication of results from a 26-patient, Phase 2 study of fosbretabulin (ZYBRESTAT) in anaplastic thyroid cancer (ATC) in the current issue of the journal THYROID.

News 2009

Like its structural analog, ZYBRESTAT (fosbretabulin / CA4P), OXi4503 has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis.

News 2009

The increase in loss from operations for the twelve month period is attributable to an increase in operating expenses which was driven primarily by a higher level of clinical development activities, including the ongoing FACT study of fosbretabulin (ZYBRESTAT) in anaplastic thyroid cancer (ATC), the FALCON study of fosbretabulin in non-small cell lung cancer (NSCLC) as well as the management of other ongoing clinical trials and drug development activities.

News 2009

The increase in loss from operations for the twelve month period is attributable to an increase in operating expenses which was driven primarily by a higher level of clinical development activities, including the ongoing FACT study of fosbretabulin (ZYBRESTAT) in anaplastic thyroid cancer (ATC), the FALCON study of fosbretabulin in non-small cell lung cancer (NSCLC) as well as the management of other ongoing clinical trials and drug development activities.

News 2009

Like its structural analog, ZYBRESTAT (TM) (fosbretabulin / CA4P), OXi4503 has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis.

News 2009

Like its structural analog, ZYBRESTAT (TM) (fosbretabulin / CA4P), OXi4503 has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis.

News 2009

Like its structural analog, ZYBRESTAT (TM) (fosbretabulin / CA4P), OXi4503 has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis.

News 2009